期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 169, 期 1, 页码 77-80出版社
WILEY-BLACKWELL
DOI: 10.1111/bjh.13262
关键词
momelotinib; neuropathy; myelofibrosis; myeloproliferative
类别
资金
- Gilead
Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32weeks and duration 11months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P=002) and longer survival (P=0048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据